NSCLC Therapy Management For Optimal Outcomes

PFIZER, S.A

Objeto

Topic: Cancer.

Destination: Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.

Budget: Up to 150,000$.

Duration: Not Indicated.

Estás interesado?

Llena el siguiente formulario para recibir más información: